ReviewFrontiers in cellular and infection microbiology2025
Anaerobic gut bacteria and their potential role in the initiation, exacerbation, and development of human colorectal cancer: a narrative review.
Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Gut Microbiota in Colorectal Cancer: Mechanisms of Carcinogenesis, Biomarkers, and Therapeutic Perspectives.Journal of clinical medicine · 2026Review
- Pathology-derived clinical micro-architectural diagnostics of tumour-microbiome interactions in colorectal cancer.Journal of translational medicine · 2026Article
- MicroRNA‑microbiome cross‑kingdom networks drive inflammatory bowel disease through dynamic regulatory ecosystems (Review).International journal of molecular medicine · 2026Review
- Recent advances in the positive role ofFrontiers in immunology · 2026Review
- Gut microbiota-innate immune crosstalk in the initiation and progression of CRC: mechanisms and therapeutic potential.Frontiers in immunology · 2026Review
- Myeloid-derived suppressor cells and regulatory T cells in colorectal cancer: a synergistic immunosuppressive axis and emerging therapeutic opportunities.Frontiers in immunology · 2026Review
- Antibiotic resistance patterns, toxin profiles, and toxin gene expression levels among Clostridioides difficile PCR ribotypes isolated from patients scheduled for colonoscopy.Molecular biology reports · 2025Article
- Carbapenem resistance in enterotoxigenic Bacteroides fragilis isolated from colonoscopy candidates.AMB Express · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is known as the second leading cause of cancer-related deaths around the world. Rectal bleeding, changes in bowel movements, weight loss, and fatigue are the main clinical presentations of CRC. While the exact etiology of the disease is unknown, CRC is considered a complex and multifactorial disease resulted from an intricate interplay of genetic and environmental factors. Moreover, CRC is known as a chronic inflammation-associated tumor, and patients with inflammatory bowel disease (IBD) or Irritable bowel syndrome (IBS) are susceptible groups to CRC development. The gut microbiota and its metabolites play a crucial role in the development and progression of CRC. CRC can be created after anaerobic bacterial infections such as Enterotoxigenic
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.